Landmark CRISPR approval; Why don’t investors like Verve’s base editing data?; Janet Woodcock to retire; Late Friday IPO filing; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

This week,…
Click here to view original post